We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+18.68%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$6.69B
AUM Growth
+$682M
Cap. Flow
-$395M
Cap. Flow %
-5.9%
Top 10 Hldgs %
54.02%
Holding
678
New
246
Increased
85
Reduced
72
Closed
235

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$85.8M
2
INDV icon
Indivior Pharmaceuticals
INDV
+$59.6M
3
BCAX
Bicara Therapeutics
BCAX
+$45.8M
4
MRUS
Merus
MRUS
+$34.4M
5
VTRS icon
Viatris
VTRS
+$30M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$102M
2
SGRY icon
Surgery Partners
SGRY
+$86.4M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$53.7M
4
IART icon
Integra LifeSciences
IART
+$42.8M
5
BNTX icon
BioNTech
BNTX
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.45%
2 Industrials 0.73%
3 Technology 0.55%
4 Financials 0.45%
5 Consumer Discretionary 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRC
576
DELISTED
MRC Global
MRC
– –
-11,269
Closed -$145K
MTRN icon
577
Materion
MTRN
$3.97B
– –
-2,287
Closed -$247K
MTSI icon
578
MACOM Technology Solutions
MTSI
$17.8B
– –
-1,856
Closed -$207K
MWA icon
579
Mueller Water Products
MWA
$3.93B
– –
-42,903
Closed -$769K
NMFC icon
580
New Mountain Finance
NMFC
$656M
– –
-18,190
Closed -$223K
NMIH icon
581
NMI Holdings
NMIH
$3.38B
– –
-26,625
Closed -$906K
NRC icon
582
NRC Health Common Stock
NRC
$410M
– –
-18,620
Closed -$427K
NRIX icon
583
Nurix Therapeutics
NRIX
$2.46B
– –
-27,507
Closed -$574K
NUVB icon
584
Nuvation Bio
NUVB
$2.3B
– –
-262,205
Closed -$766K
NWBI icon
585
Northwest Bancshares
NWBI
$2.32B
– –
-61,780
Closed -$714K
NXST icon
586
Nexstar Media Group
NXST
$6B
– –
-3,818
Closed -$634K
OBDC icon
587
Blue Owl Capital
OBDC
$5.36B
– –
-60,975
Closed -$937K
OLLI icon
588
Ollie's Bargain Outlet
OLLI
$4.36B
– –
-3,223
Closed -$316K
ON icon
589
ON Semiconductor
ON
$31.6B
– –
-4,777
Closed -$327K
OSBC icon
590
Old Second Bancorp
OSBC
$1.29B
– –
-51,219
Closed -$759K
OTIS icon
591
Otis Worldwide
OTIS
$27.8B
– –
-3,248
Closed -$313K
OWL icon
592
Blue Owl Capital
OWL
$6.51B
– –
-12,811
Closed -$227K
PAYO icon
593
Payoneer
PAYO
$2.41B
– –
-94,213
Closed -$522K
PCRX icon
594
Pacira BioSciences
PCRX
$1.04B
– –
-17,062
Closed -$488K
PH icon
595
Parker-Hannifin
PH
$120B
– –
-759
Closed -$384K
PLL
596
DELISTED
Piedmont Lithium
PLL
– –
-39,415
Closed -$393K
PLRX icon
597
Pliant Therapeutics
PLRX
$66.3M
– –
-11,678
Closed -$126K
PLUS icon
598
ePlus
PLUS
$2.48B
– –
-7,237
Closed -$533K
PRA
599
DELISTED
ProAssurance
PRA
– –
-80,425
Closed -$983K
PRGS icon
600
Progress Software
PRGS
$1.76B
– –
-16,238
Closed -$881K
22 23
24
25 26

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2024 Portfolio in Review

As of Q3 2024, Deerfield Management held 678 positions worth $6.69B, up 11% from $6.01B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Deerfield Management withdrew a net $395M in Q3 2024, closing 235 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $102M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Industrials and Technology.

Against the trend, Deerfield Management opened a new position in Indivior Pharmaceuticals worth $49.7M.

  • Deerfield Management's largest Q3 2024 buy was Indivior Pharmaceuticals: 5,092,642 shares worth $49.7M.
  • Deerfield Management added most to Neurocrine Biosciences in Q3 2024, an estimated $85.8M increase.
  • Deerfield Management's biggest Q3 2024 reduction was Surgery Partners, cutting an estimated $86.4M.
  • Deerfield Management fully exited Gilead Sciences in Q3 2024, selling an estimated $102M.
  • Deerfield Management's ten largest holdings make up 54% of its $6.69B portfolio in Q3 2024.
  • Deerfield Management opened 246 new positions and closed 235 in Q3 2024.
  • Deerfield Management's portfolio value rose 11% quarter-over-quarter to $6.69B.

Based on Deerfield Management's 13F filing for Q3 2024, filed 14 Nov 2024.